Medline (MDLN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of 12 directors is up for shareholder vote at the 2026 Annual Meeting, with board recommendations provided for each nominee.
Advisory vote to approve executive compensation is included on the ballot.
Advisory vote on the frequency of future executive compensation votes is presented, with a 1-year frequency recommended.
Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 is proposed.
Proxies may vote on other matters arising at the meeting or any adjournment.
Board of directors and corporate governance
Twelve director nominees are listed for election, including Charles N. Mills, Joseph P. Baratta, and others.
Executive compensation and say-on-pay
Shareholders are asked to approve executive compensation through an advisory vote.
Advisory vote on the frequency of executive compensation votes is included, with a 1-year interval recommended.
Latest events from Medline
- 2025 saw double-digit sales growth, a public listing, and enhanced governance and ESG focus.MDLN
Proxy filing23 Apr 2026 - 2025 saw 11.5% sales growth, record signings, and IPO success, with strong 2026 outlook.MDLN
Q4 202516 Apr 2026 - 2026 outlook targets 8%-9% organic growth, margin expansion, and continued market share gains.MDLN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - 75 million shares offered by selling stockholders; strong recurring revenue and growth outlook.MDLN
Registration Filing3 Mar 2026 - Targets high single-digit growth, $1B annual signings, and margin recovery by 2027.MDLN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Largest global med-surg supplier with strong growth, robust margins, and IPO proceeds for debt reduction.MDLN
Registration Filing16 Dec 2025 - Medline’s IPO funds growth and debt reduction, but faces risks from leverage, competition, and regulation.MDLN
Registration Filing16 Dec 2025 - Medline seeks $4.9B in IPO proceeds to reduce debt, leveraging its market leadership and integrated model.MDLN
Registration Filing16 Dec 2025